Extensive Dural Metastasis as Initial Presentation of Metastatic Prostate Cancer: A Case Report With Durable Disease Control Following Multimodal Treatment
4 affiliations
- 1Klinik für Neurochirurgie Universitätsklinikum Düsseldorf Moorenstr Düsseldorf Germany
- 2German Cancer Consortium (DKTK) Partner Site Düsseldorf and German Cancer Research Center (DKFZ) Heidelberg Germany dkfz.de
- 3Institut für Neuropathologie Universitätsklinikum Düsseldorf Moorenstr Düsseldorf Germany
- 4Klinik für Hämatologie und Onkologie Marienhospital Düsseldorf Rochusstr Düsseldorf Germany
Abstract
Central nervous system involvement in prostate cancer is rare, particularly in the form of dural or pachymeningeal metastases. We report the case of a 72‐year‐old man presenting with visual disturbances without hemianopsia, and right‐sided headache since several weeks caused by an extensive right temporal dural‐based lesion with intracranial extension. A minimally invasive frontotemporal burr‐hole biopsy was performed for histopathological clarification. Histological and immunohistochemical analyses confirmed metastatic prostatic adenocarcinoma with expression of cytokeratin 8, NKX3.1, PSA, and PSMA. Subsequent systemic staging demonstrated metastatic castration‐sensitive prostate cancer with pulmonary, lymphatic, and extensive osseous metastases. The patient underwent focal radiotherapy (36 Gy in 12 fractions) to the dural lesion and systemic treatment with androgen deprivation therapy and enzalutamide. Due to dizziness and sweating, enzalutamide dosage was reduced from 160 to 80 mg/day with maintained therapeutic response. At approximately 15 months of follow‐up, the patient remained neurologically stable with durable local disease control on cranial MRI, marked biochemical response (PSA decline from 177 to 0.6 ng/mL), and no evidence of systemic progression. This case highlights the importance of considering metastatic prostate cancer in the differential diagnosis of dural‐based intracranial lesions in elderly men and demonstrates that individualized multimodal treatment can achieve durable disease control even in rare metastatic presentations.
Related
- Orbital metastasis revealing occult metastatic prostate adenocarcinoma in a South African man: A rare initial ophthalmic presentation
- Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma (AESOP) Syndrome Associated With a Solitary Bone Plasmacytoma of the Left Scapula: A Rare Paraneoplastic Presentation Managed With High-Precision Radiotherapy
- Primary renal Ewing sarcoma with extensive metastatic disease at diagnosis: A case report and literature review
- Emphysematous gastritis with extensive portal venous gas and endoscopic mucosal necrosis: gastric preservation despite an alarming presentation.
- Pseudo-peritoneal carcinomatosis: extensive endosalpingiosis mimicking metastatic dissemination in gastric cancer : a case report and literature review.
BibTeX
@article{wasilewski2026extensive,
title = {{Extensive Dural Metastasis as Initial Presentation of Metastatic Prostate Cancer: A Case Report With Durable Disease Control Following Multimodal Treatment}},
author = {David Wasilewski and Jörg Felsberg and Theodoros Tzamalis and Sajjad Muhammad},
journal = {Case Reports in Urology},
year = {2026},
month = nov,
doi = {10.1155/criu/1896431},
url = {https://doi.org/10.1155/criu/1896431},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Extensive Dural Metastasis as Initial Presentation of Metastatic Prostate Cancer: A Case Report With Durable Disease Control Following Multimodal Treatment
AU - David Wasilewski
AU - Jörg Felsberg
AU - Theodoros Tzamalis
AU - Sajjad Muhammad
PY - 2026
DA - 2026/11/04
JO - Case Reports in Urology
DO - 10.1155/criu/1896431
UR - https://doi.org/10.1155/criu/1896431
AB - Central nervous system involvement in prostate cancer is rare, particularly in the form of dural or pachymeningeal metastases. We report the case of a 72‐year‐old man presenting with visual disturbances without hemianopsia, and right‐sided headache since several weeks caused by an extensive right temporal dural‐based lesion with intracranial extension. A minimally invasive frontotemporal burr‐hole biopsy was performed for histopathological clarification. Histological and immunohistochemical analyses confirmed metastatic prostatic adenocarcinoma with expression of cytokeratin 8, NKX3.1, PSA, and PSMA. Subsequent systemic staging demonstrated metastatic castration‐sensitive prostate cancer with pulmonary, lymphatic, and extensive osseous metastases. The patient underwent focal radiotherapy (36 Gy in 12 fractions) to the dural lesion and systemic treatment with androgen deprivation therapy and enzalutamide. Due to dizziness and sweating, enzalutamide dosage was reduced from 160 to 80 mg/day with maintained therapeutic response. At approximately 15 months of follow‐up, the patient remained neurologically stable with durable local disease control on cranial MRI, marked biochemical response (PSA decline from 177 to 0.6 ng/mL), and no evidence of systemic progression. This case highlights the importance of considering metastatic prostate cancer in the differential diagnosis of dural‐based intracranial lesions in elderly men and demonstrates that individualized multimodal treatment can achieve durable disease control even in rare metastatic presentations.
SN - 2090-696X
SN - 2090-6978
ER -